Replimune Group, Inc. director Veleka Peeples-Dyer filed a Form 144 notice of proposed sale on November 17, 2026, covering 34,500 shares of common stock to be sold through Morgan Stanley Smith Barney LLC.
Key Highlights
- Proposed sale size: 34,500 shares of Replimune Group common stock, with an aggregate market value of $693,544.50 as stated in the filing.
- Source of shares: The securities were acquired on November 17, 2026 via a stock option exercise from the issuer, with payment made in cash on the same date.
- Selling party: Veleka Peeples-Dyer, identified as a director of Replimune Group, Inc.
- Shares outstanding: The filing reports 94,800,404 shares of common stock outstanding.
- Prior sales reported: The filing discloses two sales in the prior three months: 12,000 shares sold on October 28, 2026 for gross proceeds of $154,744.80, and 10,000 shares sold on October 30, 2026 for gross proceeds of $167,232.00.
- Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
Peeples-Dyer's Proposed Stock Option Exercise and Sale at Replimune Group
According to the Form 144 filing dated November 17, 2026, Veleka Peeples-Dyer, a director of Replimune Group, Inc. (NASDAQ:REPL), provided notice of a proposed sale of 34,500 shares of the company's common stock. The filing states the aggregate market value of those shares is $693,544.50. The shares are to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing discloses that the 34,500 shares were acquired on November 17, 2026 through a stock option exercise from the issuer, with cash payment made on the same date. Replimune Group is headquartered at 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801, and carries SEC File Number 001-38596. The filing reports total shares of common stock outstanding at 94,800,404.
In the section covering securities sold in the prior three months, the filing lists two additional transactions by Peeples-Dyer: a sale of 12,000 shares on October 28, 2026, generating gross proceeds of $154,744.80, and a sale of 10,000 shares on October 30, 2026, generating gross proceeds of $167,232.00. The notice was signed by Veleka Peeples-Dyer and dated November 17, 2026.
What Was Disclosed
A Form 144 filed by Replimune Group director Veleka Peeples-Dyer on November 17, 2026 disclosed the proposed sale of 34,500 shares of common stock acquired via stock option exercise, plus two prior sales totaling 22,000 shares completed in October 2026.




Please wait processing your request...